ESR1 and breast carcinoma: Briefly, we demonstrated that ER+ breast cancer cell lines resistant to the combination of fulvestrant and abemaciclib (MCF7-FAR and T47D-FAR) developed an increased anchorage-independent growth and invasive phenotype.